Tardive Dyskinesia

This FDA approval could relieve patients of several neurological side effects.

Results from a six-week study show patients with major depressive disorder treated with brexpiprazole had significantly reduced risk of akathisia and other side effects.

Genotyping and access to more genetic information about patients may allow clinicians to minimize side effects associated with treatment for schizophrenia by choosing antipsychotic agents based on their unique molecular binding profiles and using the lowest effective doses.

Patients with advanced Parkinson's disease treated with an investigational extended-release carbidopa-levodopa formulation experienced greater reductions in "off" time and greater improvement in dyskinesia-free "on" time compared with similar patients treated with carbidopa-levodopa plus entacapone.

From a pharmacologic perspective metoclopramide is much closer to antipsychotic drugs, in that it is, in part, a blocker of central dopamine receptors.